SEE OUR TECHNOLOGY

Our Clinical Trial

Our malaria vaccine candidate VLPM01 clinical trial designed to evaluate the safety, tolerability, immunogenicity and experimental efficacy of VLPM01 in healthy, malaria-naïve adult volunteers. The study will be conducted at the Walter Reed Army Institute of Research in Silver Spring, Maryland (WRAIR), as this institute has extensive experience in conducting clinical studies of malaria vaccines with Controlled Human Malaria Infection (CHMI). A total of 36 participants will be enrolled in this study.

For more information (ClinicalTrials.gov)

Contact the WRAIR Clinical Trials Center Recruitment Office  Phone: 1-866-4-CTC-STUDY (866-428-2788).

Our Platform Technologies

Surface Antigen Display

i-αVLP Platform

Cancer Vaccine

Malaria Vaccine

Interior Gene Delivery

Replicon Platform

Cancer Therapy

Native Virus Modification

Native Virus Vaccines

Dengue Vaccine

3108, 2020

VLP Therapeutics Japan, a wholly owned subsidiary of VLP Therapeutics, has been selected by the Japanese government AMED fund for development of a protective vaccine against the new coronavirus infectious disease (COVID-19)

August 31, 2020   Gaithersburg, MD – VLP Therapeutics announced today that VLP Therapeutics Japan (VLPTJ), a wholly owned subsidiary of VLP Therapeutics, has been selected to receive Japanese government funding through the AMED Fund